539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study
Year: 2020
Type: article
Source: Annals of Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, University of Colorado Anschutz, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Hospital Universitario 12 De Octubre, Centre Léon Bérard, University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Samsung Medical Center, National Hospital Organization Kyushu Cancer Center, National University Cancer Institute, Singapore, The Maria Sklodowska-Curie National Research Institute of Oncology, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, Evangelische Lungenklinik Berlin, Istituto Oncologico Veneto, Virginia Cancer Specialists, Princess Margaret Hospital, Genentech, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3088629835